J Korean Diabetes.  2023 Sep;24(3):141-147. 10.4093/jkd.2023.24.3.141.

2023 Clinical Practice Guidelines for Diabetes: Continuous Glucose Monitoring and Insulin Pumps

• Jin SM

• KMID: 2546631
• DOI: http://doi.org/10.4093/jkd.2023.24.3.141

Abstract

With the expanding use of continuous glucose monitoring (CGM) and insulin pumps worldwide, several international guidelines dedicated to diabetes technology have been developed. Recently, the Korean Diabetes Association released a new version of their clinical practice guidelines including substantial changes in recommendations on the use of CGM and insulin pumps. Of note, continuous use of real-time CGM is now recommended to all people with diabetes using insulin, including people with type 2 diabetes using once daily basal insulin. Convincing evidence from recent automated insulin delivery (AID) trials supports the recommendation of AID as standard therapy in type 1 diabetes. This review summarizes the results of recent clinical studies on CGM and AID and their influence on the new clinical recommendations.

Keyword

Automation; Blood glucose self-monitoring; Diabetes mellitus, type 1; Insulin infusion systems

Reference

1.Beck RW., Riddlesworth T., Ruedy K., Ahmann A., Bergenstal R., Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017. 317:371–8.

2.Lind M., Polonsky W., Hirsch IB., Heise T., Bolinder J., Dahlqvist S, et al. Continuous glucose monitoring vs con-ventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017. 317:379–87.

3.Tumminia A., Crimi S., Sciacca L., Buscema M., Frittitta L., Squatrito S, et al. Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev. 2015. 31:61–8.

4.Sequeira PA., Montoya L., Ruelas V., Xing D., Chen V., Beck R, et al. Continuous glucose monitoring pilot in low-in-come type 1 diabetes patients. Diabetes Technol Ther. 2013. 15:855–8.

5.Tamborlane WV., Beck RW., Bode BW., Buckingham B., Chase HP., Clemons R., Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008. 359:1464–76.

6.Battelino T., Conget I., Olsen B., Schütz-Fuhrmann I., Hommel E., Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012. 55:3155–62.

7.Deiss D., Bolinder J., Riveline JP., Battelino T., Bosi E., Tubiana-Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006. 29:2730–2.

8.O'Connell MA., Donath S., O'Neal DN., Colman PG., Ambler GR., Jones TW, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009. 52:1250–7.

9.Bolinder J., Antuna R., Geelhoed-Duijvestijn P., Kröger J., Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016. 388:2254–63.

10.Hermanns N., Schumann B., Kulzer B., Haak T. The impact of continuous glucose monitoring on low interstitial glucose values and low blood glucose values assessed by point-of-care blood glucose meters: results of a crossover trial. J Diabetes Sci Technol. 2014. 8:516–22.

11.van Beers CA., DeVries JH., Kleijer SJ., Smits MM., Geel-hoed-Duijvestijn PH., Kramer MH, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016. 4:893–902.

12.Heinemann L., Freckmann G., Ehrmann D., Faber-Heine-mann G., Guerra S., Waldenmaier D, et al. Real-time con-tinuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018. 391:1367–77.

13.Beck RW., Hirsch IB., Laffel L., Tamborlane WV., Bode BW., Buckingham B., Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009. 32:1378–83.

14.Battelino T., Phillip M., Bratina N., Nimri R., Oskarsson P., Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011. 34:795–800.

15.Seyed Ahmadi S., Westman K., Pivodic A., Ólafsdóttir AF., Dahlqvist S., Hirsch IB, et al. The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: a randomized clinical trial (GOLD-4). Diabetes Care. 2020. 43:2017–24.

16.Beck RW., Riddlesworth TD., Ruedy K., Ahmann A., Haller S., Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017. 167:365–74.

17.Haak T., Hanaire H., Ajjan R., Hermanns N., Riveline JP., Rayman G. Flash glucose-sensing technology as a replace-ment for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017. 8:55–73.

18.Martens T., Beck RW., Bailey R., Ruedy KJ., Calhoun P., Peters AL, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021. 325:2262–72.

19.Aleppo G., Beck RW., Bailey R., Ruedy KJ., Calhoun P., Peters AL, et al. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. Diabetes Care. 2021. 44:2729–37.

20.Vigersky RA., Fonda SJ., Chellappa M., Walker MS., Ehrhardt NM. Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012. 35:32–8.

21.Ehrhardt NM., Chellappa M., Walker MS., Fonda SJ., Vigersky RA. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011. 5:668–75.

22.Yoo HJ., An HG., Park SY., Ryu OH., Kim HY., Seo JA, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2008. 82:73–9.

23.Choe HJ., Rhee EJ., Won JC., Park KS., Lee WY., Cho YM. Effects of patient-driven lifestyle modification using in-termittently scanned continuous glucose monitoring in patients with type 2 diabetes: results from the randomized open-label pdf study. Diabetes Care. 2022. 45:2224–30.

24.Moon SJ., Kim KS., Lee WJ., Lee MY., Vigersky R., Park CY. Efficacy of intermittent short-term use of a real-time con-tinuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2023. 25:110–20.

25.Brown SA., Kovatchev BP., Raghinaru D., Lum JW., Buckingham BA., Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019. 381:1707–17.

26.Tauschmann M., Thabit H., Bally L., Allen JM., Hartnell S., Wilinska ME, et al. Closed-loop insulin delivery in subop-timally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018. 392:1321–9.

27.Bergenstal RM., Nimri R., Beck RW., Criego A., Laffel L., Schatz D, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021. 397:208–19.

28.Šoupal J., Petruželková L., Grunberger G., Hásková A., Flekač M., Matoulek M, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of fol-low-up from the COMISAIR study. Diabetes Care. 2020. 43:37–43.

29.Bergenstal RM., Klonoff DC., Garg SK., Bode BW., Mere-dith M., Slover RH, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013. 369:224–32.

30.Forlenza GP., Li Z., Buckingham BA., Pinsker JE., Cengiz E., Wadwa RP, et al. Predictive low-glucose suspend re-duces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care. 2018. 41:2155–61.